Holen Sie sich die Stockscreener-App
37.67
4.67%
1.68
Handel nachbörslich:
37.57
-0.10
-0.27%
Schlusskurs vom Vortag:
$35.99
Offen:
$36.1
24-Stunden-Volumen:
1.56M
Relative Volume:
1.24
Marktkapitalisierung:
$2.89B
Einnahmen:
$13.17M
Nettoeinkommen (Verlust:
$-199.06M
KGV:
-13.75
EPS:
-2.74
Netto-Cashflow:
$-156.53M
1W Leistung:
+9.92%
1M Leistung:
+16.95%
6M Leistung:
-4.05%
1J Leistung:
-2.91%
1-Tages-Spanne:
$35.98
$38.05
1-Wochen-Bereich:
$32.78
$38.05
52-Wochen-Spanne:
$26.74
$46.00
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
Firmenname
Xenon Pharmaceuticals Inc
Sektor
Branche
Telefon
(604) 484-3300
Adresse
200 - 3650 GILMORE WAY, BURNABY
Vergleichen Sie XENE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
37.67 | 2.76B | 13.17M | -199.06M | -156.53M | -2.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-07 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-10-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-01-04 | Eingeleitet | Citigroup | Buy |
| 2023-12-08 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-04-25 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-12-14 | Eingeleitet | Goldman | Buy |
| 2022-12-12 | Eingeleitet | Cowen | Outperform |
| 2022-11-28 | Eingeleitet | Wells Fargo | Overweight |
| 2022-10-19 | Eingeleitet | Raymond James | Outperform |
| 2022-08-29 | Eingeleitet | BofA Securities | Buy |
| 2022-07-21 | Eingeleitet | JP Morgan | Overweight |
| 2021-10-28 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-10-02 | Eingeleitet | SVB Leerink | Outperform |
| 2020-07-21 | Eingeleitet | Needham | Buy |
| 2020-06-01 | Fortgesetzt | Jefferies | Buy |
| 2020-03-25 | Eingeleitet | Wedbush | Outperform |
| 2020-01-08 | Eingeleitet | William Blair | Outperform |
| 2019-09-20 | Eingeleitet | Guggenheim | Buy |
| 2018-08-08 | Bestätigt | Stifel | Buy |
| 2017-03-13 | Eingeleitet | Jefferies | Buy |
| 2016-10-21 | Eingeleitet | Stifel | Buy |
| 2016-09-26 | Eingeleitet | Guggenheim | Buy |
| 2016-04-14 | Bestätigt | Jefferies | Buy |
| 2015-10-30 | Fortgesetzt | Jefferies | Buy |
| 2014-12-02 | Eingeleitet | Canaccord Genuity | Buy |
Alle ansehen
Xenon Pharmaceuticals Inc Aktie (XENE) Neueste Nachrichten
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q2 2025 Earnings Call Transcript - Insider Monkey
TD Cowen Reaffirms Their Buy Rating on Xenon (XENE) - The Globe and Mail
Xenon Completes Patient Recruitment for Phase 3 Study - The Globe and Mail
Xenon Pharmaceuticals: Azetukalner's 2026 Data Readouts and Multi-Indication Launch Potential - AInvest
Xenon Pharmaceuticals: Pushing Azetukalner Towards Finish Line With Phase 3 2026 Data Release - Seeking Alpha
Xenon Pharmaceuticals shares rise 7.40% intraday after reporting positive Phase 3 study progress and commercial officer appointment. - AInvest
Xenon Q2 Loss Wider Than Expected, Pipeline Development in Focus - Nasdaq
Xenon Pharma Q2 2025 Earnings Preview - MSN
RBC Capital Adjusts Price Target on Xenon Pharmaceuticals to $55 From $57, Maintains Outperform Speculative Risk Rating - MarketScreener
Deutsche Bank Adjusts Xenon Pharmaceuticals Price Target to $57 From $60, Maintains Buy Rating - MarketScreener
Xenon targets NDA filing for azetukalner within 6 months of phase III readout while advancing late-stage neuropsychiatric programs - MSN
Xenon Pharmaceuticals shares rise 7.04% premarket after reporting positive Phase 3 study progress and commercial officer appointment. - AInvest
Compass Pathways shares fall 2.53% premarket after Xenon Pharmaceuticals reports Q2 2025 financial results. - AInvest
Xenon Pharmaceuticals Inc (XENE) Q2 2025 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Xenon Pharmaceuticals Reports Q2 2025 Progress and Outlook - TipRanks
Xenon Pharmaceuticals Q2 2025 Earnings Call Transcript: Key Highlights - AInvest
Xenon Pharmaceuticals' Q2 2025: Navigating Contradictions in X-TOLE2 Enrollment, Dosing, and Safety Strategies - AInvest
Xenon Pharmaceuticals' Azetukalner: A High-Potential Biotech Catalyst Ahead of 2026 Topline Data - AInvest
Xenon Pharmaceuticals: Q2 Earnings Snapshot - San Francisco Chronicle
Transcript : Xenon Pharmaceuticals Inc., Q2 2025 Earnings Call, Aug 11, 2025 - MarketScreener
Xenon Pharmaceuticals jumps after massive earnings beat - Investing.com India
Xenon Pharmaceuticals Inc. SEC 10-Q Report - TradingView
Xenon Pharmaceuticals Q2 Loss Widens, CFO Changes Announced - AInvest
Xenon Pharmaceuticals' Q2 2025 Earnings: A Catalyst for Neuroscience Innovation and Shareholder Value - AInvest
Xenon Pharmaceuticals Q2 Loss Widens - MarketScreener
Xenon Pharmaceuticals: A High-Conviction Play in Neurological Therapeutics with Azetukalner in Late-Stage Development - AInvest
Xenon Reports Second Quarter 2025 Financial Results & Business Update - GlobeNewswire
RBC Raises Xenon Price Target, Cites Phase III Optimism for Epilepsy Drug - MSN
Signal strength of Xenon Pharmaceuticals Inc. stock in tech scannersFree Consistent Income Focused Trade List - Newser
Is Xenon Pharmaceuticals Inc. a candidate for recovery playDay Trading Setup Forecast with Trend Model - Newser
Institutional scanner results for Xenon Pharmaceuticals Inc.AI Intraday Market Movement Prediction Tool - Newser
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Acquired by Natixis Advisors LLC - Defense World
Should I buy Xenon Pharmaceuticals Inc. stock before earningsInvestment Timing Strategy with Market Filters - Newser
Published on: 2025-08-11 01:10:41 - Newser
Best data tools to analyze Xenon Pharmaceuticals Inc. stockStock Trading Session Highlights and Summary - Newser
Momentum divergence signals in Xenon Pharmaceuticals Inc. chartDaily Market Movers Screener with Filters - Newser
Quantitative breakdown of Xenon Pharmaceuticals Inc. recent moveFree AI Trading Suggestions With Accuracy Focus - Newser
Will a bounce in Xenon Pharmaceuticals Inc. offer an exitAI Risk Optimized Trade Forecast Planner - Newser
Measuring Xenon Pharmaceuticals Inc.’s beta against major indicesDaily Technical Chart Pattern Analysis Report - Newser
Xenon Pharmaceuticals Inc. stock trendline breakdownHigh Yield Signals with Entry Timing - Newser
Xenon Pharmaceuticals (XENE) to Release Earnings on Monday - Defense World
Is it too late to sell Xenon Pharmaceuticals Inc.Short Term Gain Strategy with AI Logic - Newser
Xenon Pharmaceuticals XENE 2025Q2 Earnings Preview Upside Potential on Innovative Product Launches - AInvest
Xenon Pharmaceuticals Inc expected to post a loss of 99 cents a shareEarnings Preview - TradingView
Fund Update: GEODE CAPITAL MANAGEMENT, LLC added 900,746 shares of XENON PHARMACEUTICALS ($XENE) to their portfolio - Quiver Quantitative
Zurcher Kantonalbank Zurich Cantonalbank Sells 318 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:XENE) - Defense World
Will Xenon Pharmaceuticals Inc. continue its uptrendMonthly Trade Result and Signal Summary - Newser
Xenon Pharmaceuticals Skyrockets 8.9%—What’s Fueling This Biotech Breakout? - AInvest
Xenon Pharmaceuticals to Announce Q2 2025 Financial Results - The Globe and Mail
Is Xenon Pharmaceuticals Inc. stock poised for growthFree Target Return Focused Trade Insights - Newser
Finanzdaten der Xenon Pharmaceuticals Inc-Aktie (XENE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):